Vitality Biopharma Inc. (VBIO) 0.9599 $VBIO Vit
Post# of 273249
Vitality Biopharma Develops Cannabinoid Alternatives to Opiate Prescription Pain Medications
Marketwired - Tue Sep 13, 8:02AM CDT
Cannabosides Enable Targeted Pain Relief and Avoid Psychoactivity of THC Through Site-Specific Delivery
Vitality Biopharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Marketwired - Mon Sep 12, 12:50PM CDT
LOS ANGELES, CA--(Marketwired - Sep 12, 2016) - Vitality Biopharma, Inc. (OTCQB: VBIO) ("Vitality" or the "Company" a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders announced today that Company CEO, Robert Brooke will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference to be held September 12, 2016, at the Lotte New York Palace Hotel in New York City.
Vitality Biopharma Announces Expansion of Prodrug Pharmaceutical Portfolio
Marketwire Canada - Wed Aug 24, 8:01AM CDT
Company Protects Intellectual Property Addressing Solution That Over 50 Pharma Companies Have Invested More Than $1B to Research